Overview

• Pregnancy diagnostics firm's Q1 revenue fell sharply yr/yr

• Net loss for Q1 widened slightly from prior year

• Company extended cash runway through 2029 after cost structure changes

Outlook

• Company expects cash resources to fund operations through 2029

• Company advancing toward CE marking in Europe with regulatory submission on track for mid-year

• Company focusing on commercialization and expanding clinician engagement in targeted markets

Result Drivers

• COMMERCIAL INVESTMENT - Co said higher selling, general and administrative expenses reflected targeted commercial activities and strategic headcount additions after PRIME study publication

• SHIFT TO COMMERCIALIZATION - Co said it redirected investment from clinical spend toward reimbursement-driven commercialization, aiming for a sustainable cost structure

Company press release: ID:nPn2BLzLna

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the business support services peer group is "buy"

• Wall Street's median 12-month price target for Sera Prognostics Inc is $5.00, about 166% above its May 5 closing price of $1.88

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.